- Research works
- 0 fractional, all time
- Citations
- 1 10.0 per fractional work
- Top-10% rate
- 30.0% record average 16.5%
- Open access
- 29% world 28%
Not ranked overall: Synthomics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Synthomics (United States) publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Lung Cancer Research Studies and Lung Cancer Treatments and Mutations.
- 1 Cancer Immunotherapy and Biomarkers Oncology 0 works
- 2 CAR-T cell therapy research Oncology 0 works
- 3 Lung Cancer Research Studies Oncology 0 works
- 4 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
- 5 Biosimilars and Bioanalytical Methods Immunology 0 works
- 6 Chemokine receptors and signaling Oncology 0 works
- 7 Immunotherapy and Immune Responses Immunology 0 works
- 8 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
- 9 Nanowire Synthesis and Applications Biomedical Engineering 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
Other research institutions in Menlo Park
- SRI International
- SLAC National Accelerator Laboratory
- Stanford Synchrotron Radiation Lightsource
- Exponent (United States)
- Kavli Institute for Particle Astrophysics and Cosmology
- Meta (United States)
- Pacific Biosciences (United States)
- Linac Coherent Light Source
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.